MCID: ANP001
MIFTS: 56

Anaplastic Large Cell Lymphoma

Categories: Rare diseases, Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Anaplastic Large Cell Lymphoma:

Name: Anaplastic Large Cell Lymphoma 38 12 50 56 29 52 14
Alcl 50 56
Cd30 Positive Anaplastic Large Cell Lymphoma 56
Ki-1 Positive Anaplastic Large Cell Lymphoma 56
Ki-1+ Anaplastic Large Cell Lymphoma 69
Primary Systemic Alcl 56
Sacl 56

Characteristics:

Orphanet epidemiological data:

56
anaplastic large cell lymphoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050744
Orphanet 56 ORPHA98841
MESH via Orphanet 43 D017728
UMLS via Orphanet 70 C0206180
ICD10 via Orphanet 34 C84.6 C84.7

Summaries for Anaplastic Large Cell Lymphoma

Disease Ontology : 12 A non-Hodgkin lymphoma involving aberrant T-cells.

MalaCards based summary : Anaplastic Large Cell Lymphoma, also known as alcl, is related to hemolytic anemia and alk-positive anaplastic large cell lymphoma. An important gene associated with Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Adcetris and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and breast, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Wikipedia : 72 Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving aberrant T cells or... more...

Related Diseases for Anaplastic Large Cell Lymphoma

Diseases in the Anaplastic Large Cell Lymphoma family:

Anaplastic Small Cell Lymphoma

Diseases related to Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
id Related Disease Score Top Affiliating Genes
1 hemolytic anemia 29.5 ALK NPM1 PAX5 TNFRSF8
2 alk-positive anaplastic large cell lymphoma 12.5
3 alk-negative anaplastic large cell lymphoma 12.5
4 primary cutaneous anaplastic large cell lymphoma 12.3
5 lymphoma 11.2
6 anaplastic small cell lymphoma 11.2
7 pancreatic intraductal papillary-colloid carcinoma 10.5 MUC1 STAT3
8 macrocephaly, mental retardation, short stature, spastic paraplegia and cns malformations 10.5 ALK GZMB NPM1
9 mixed extragonadal germ cell cancer 10.5 ALK NPM1 RNF213
10 penile disease 10.5 ALK PTPRC TNFRSF8
11 estrogen-receptor positive breast cancer 10.5 ALK NPM1 PTPRC
12 lymphomatoid papulosis 10.4
13 leg dermatosis 10.4 CLU CSF1R
14 short-rib thoracic dysplasia 12 10.4 MUC1 PTPRC TNFRSF8
15 brain stem infarction 10.4 PTPRC TNFRSF8
16 glossopharyngeal nerve neoplasm 10.4 CSF1R PTPRC TNFRSF8
17 hodgkin lymphoma 10.4
18 malignant sertoli-leydig cell tumor 10.3 PAX5 TNFRSF8
19 esophageal adenosquamous carcinoma 10.3 CLU PTPRC
20 plummer vinson syndrome 10.3 MUC1 PTPRC
21 ovarian cystic teratoma 10.2 PTPRC TNFRSF8
22 pediatric lymphoma 10.2 GZMB PAX5
23 b-cell lymphomas 10.2
24 leukemia 10.2
25 villoglandular endometrial endometrioid adenocarcinoma 10.2 GZMB PAX5 TNFRSF8
26 severe combined immune deficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative, jak3-related 10.1 IL9 JAK3
27 cholesteatoma 10.1 NPM1 PAX5 PTPRC
28 peripheral t-cell lymphoma 10.1
29 hemophagocytic lymphohistiocytosis 10.1
30 inflammatory myofibroblastic tumor 10.1
31 diffuse large b-cell lymphoma 10.1
32 sarcoma 10.1
33 childhood spinal cord tumor 10.0 PTPRC TNFRSF8
34 drug-induced hepatitis 10.0 ALK PAX5 STAT3 TNFRSF8
35 histiocytosis 10.0
36 cerebritis 10.0
37 dermatitis 10.0
38 mycosis fungoides 10.0
39 epstein-barr virus, susceptibility to chronic infection by 10.0 CLU GZMB STAT3 TNFRSF8
40 chronic intestinal vascular insufficiency 10.0 ALK PAX5 PTPRC TNFRSF8
41 congenital sucrase-isomaltase deficiency with starch intolerance 10.0 ALK GZMB MUC1 NPM1 PTPRC
42 adult t-cell leukemia 9.9
43 myeloid leukemia 9.9
44 panniculitis 9.9
45 soft tissue sarcoma 9.9
46 t-cell leukemia 9.9
47 pmm2-congenital disorder of glycosylation 9.9 IL9 JAK3
48 childhood cerebellar astrocytic neoplasm 9.9 IL9 JAK3 PTPRC
49 pyogenic granuloma 9.9
50 breast cancer 9.9

Graphical network of the top 20 diseases related to Anaplastic Large Cell Lymphoma:



Diseases related to Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Anaplastic Large Cell Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.86 ALK CSF1R JAK3 MCL1 PTPRC RNF213
2 hematopoietic system MP:0005397 9.85 IL9 JAK3 JUNB MCL1 NPM1 PAX5
3 immune system MP:0005387 9.73 CLU CSF1R IL9 JAK3 JUNB MCL1
4 neoplasm MP:0002006 9.1 ALK JUNB NPM1 PAX5 PTPRC STAT3

Drugs & Therapeutics for Anaplastic Large Cell Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011

Drugs for Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 395)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 23214-92-8 31703
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
6
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
10
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
11
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
12
Vindesine Approved Phase 4 59917-39-4, 53643-48-4 40839
13
Mechlorethamine Approved Phase 4,Phase 1,Phase 2 51-75-2 4033
14
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
15
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
16
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
17
Epirubicin Approved Phase 4 56420-45-2 41867
18
Crizotinib Approved Phase 4,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
21
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2 31703
22
Pirarubicin Investigational Phase 4 72496-41-4
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
26 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
33 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
38 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
40 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
43 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
44 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Hormones Phase 4,Phase 3,Phase 2,Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1
49 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
50 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 355)

id Name Status NCT ID Phase Drugs
1 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4 brentuximab vedotin
5 A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
6 Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
7 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed NCT00059839 Phase 3 doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;vinblastine sulfate;vincristine sulfate
12 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
13 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
14 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
16 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
17 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
19 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
20 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
21 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
22 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
23 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
24 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
25 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
26 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
27 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
28 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
29 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
30 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
31 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
32 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate or Bexarotene
33 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
36 CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Unknown status NCT02274584 Phase 1, Phase 2
37 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00073957 Phase 2 cytarabine;liposomal cytarabine;methotrexate
38 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Unknown status NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;vincristine sulfate;pralatrexate
39 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2 lenalidomide;carmustine;etoposide;cytarabine;melphalan
40 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
41 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
42 Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse Unknown status NCT00069966 Phase 2 cisplatin;cytarabine;methylprednisolone;pixantrone dimaleate
43 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
44 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
45 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
46 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
47 Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Completed NCT00079755 Phase 2 SGN-30 (anti-CD30 mAb)
48 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed NCT00117988 Phase 2 tanespimycin
49 Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Completed NCT00099255 Phase 2 SGN-30
50 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed NCT00866047 Phase 2 brentuximab vedotin

Search NIH Clinical Center for Anaplastic Large Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Anaplastic Large Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Anaplastic Large Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Anaplastic Large Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Anaplastic Large Cell Lymphoma

Genetic tests related to Anaplastic Large Cell Lymphoma:

id Genetic test Affiliating Genes
1 Anaplastic Large Cell Lymphoma 29

Anatomical Context for Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Anaplastic Large Cell Lymphoma:

39
T Cells, Bone, Breast, Bone Marrow, B Cells, Liver, Skin

Publications for Anaplastic Large Cell Lymphoma

Articles related to Anaplastic Large Cell Lymphoma:

(show top 50) (show all 997)
id Title Authors Year
1
Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema. ( 28337783 )
2017
2
Bariatric Implant-Associated Anaplastic Large-Cell Lymphoma. ( 28945505 )
2017
3
Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma. ( 28775121 )
2017
4
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. ( 28522440 )
2017
5
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. ( 28787259 )
2017
6
Discussion: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. ( 28953714 )
2017
7
Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex. ( 27840423 )
2017
8
Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma. ( 28414323 )
2017
9
Discussion: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. ( 28953712 )
2017
10
Re: Breast implant associated anaplastic large cell lymphoma in Australia and New Zealand - high surface area textured implants are associated with increased risk. ( 28938346 )
2017
11
Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma. ( 28665006 )
2017
12
Primary gastrointestinal anaplastic large cell lymphoma. ( 28693749 )
2017
13
Primary Bone Anaplastic Large Cell Lymphoma Masquerading as Ewing Sarcoma: Diagnosis by Anchored Multiplex PCR. ( 28452858 )
2017
14
Implications of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) for Breast Cancer Reconstruction: An Update for Surgical Oncologists. ( 28762113 )
2017
15
Characteristics And Outcomes Of Anaplastic Large Cell Lymphoma Patients-A Single Centre Experience. ( 28712170 )
2017
16
Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in theA pre-brentuximab vedotin era: A LYSA/SFGM-TC study. ( 28735072 )
2017
17
ALK-positive anaplastic large cell lymphoma undiagnosed in a patient with tuberculosis: a case report and review of the literature. ( 28490385 )
2017
18
Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. ( 27766622 )
2017
19
NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma. ( 27694894 )
2017
20
Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma. ( 28857122 )
2017
21
Reply: Breast implant associated anaplastic large cell lymphoma in Australia and New Zealand - high surface area textured implants are associated with increased risk. ( 28938349 )
2017
22
Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation. ( 28497585 )
2017
23
The long non-coding RNA LINC01013 enhances invasion of human anaplastic large-cell lymphoma. ( 28331184 )
2017
24
Breast implant-associated anaplastic large cell lymphoma: A review and assessment of cutaneous manifestations. ( 28831423 )
2017
25
Myxoid variant of primary cutaneous anaplastic large cell lymphoma: First 2 cases. ( 28626950 )
2017
26
Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma. ( 28715445 )
2017
27
Pyogenic variant of primary cutaneous CD30+ anaplastic large-cell lymphoma: Spontaneous remission in a young adult. ( 28834152 )
2017
28
Discussion: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. ( 28953715 )
2017
29
Primary cutaneous anaplastic large cell lymphoma. ( 28342276 )
2017
30
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. ( 28344319 )
2017
31
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of ALK-Positive Anaplastic Large Cell Lymphoma. ( 28675026 )
2017
32
Composite lymphoma with coexistence of diffuse large B-cell lymphoma and anaplastic large cell lymphoma: Diagnostic pitfalls. ( 28631654 )
2017
33
A case of CD30+ ALK1- anaplastic large cell lymphoma resembling acute disseminated encephalomyelitis. ( 28427693 )
2017
34
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. ( 28370436 )
2017
35
Small cell variant of anaplastic large cell lymphoma with leukemic presentation: a diagnostic challenge. ( 28830608 )
2017
36
ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. ( 28139895 )
2017
37
Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. ( 28878445 )
2017
38
Indolent ALK-Negative Anaplastic Large Cell Lymphoma, DUSP22 Rearranged, with an Unusual Immunophenotype in an HIV Patient. ( 28042680 )
2017
39
Anaplastic large cell lymphoma: A great mimic on cytology. ( 28701833 )
2017
40
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. ( 28381153 )
2017
41
Discussion: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. ( 28953713 )
2017
42
The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma. ( 26709646 )
2016
43
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large cell lymphoma. ( 27037558 )
2016
44
Discussion: Anaplastic Large Cell Lymphoma in the Plastic Surgery Practice: Has It Influenced Practice Patterns? ( 27782988 )
2016
45
Breast Implant Informed Consent Should Include the Risk of Anaplastic Large Cell Lymphoma. ( 27018666 )
2016
46
Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma. ( 26984254 )
2016
47
Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report and Literature Review. ( 27158575 )
2016
48
ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. ( 27263791 )
2016
49
A Snowy White Stomach, Caused by Primary Gastric Anaplastic Large-Cell Lymphoma. ( 27546582 )
2016
50
Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. ( 27486201 )
2016

Variations for Anaplastic Large Cell Lymphoma

Copy number variations for Anaplastic Large Cell Lymphoma from CNVD:

7 (show all 11)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19994 1 152394403 152431233 Translate TPM3 Anaplastic large cell lymphoma
2 122442 18 56200000 78077248 Loss Anaplastic large cell lymphoma
3 154895 20 49800000 58400000 Gain Anaplastic large cell lymphoma
4 154985 20 5100000 42100000 Gain Anaplastic large cell lymphoma
5 166394 3 101910849 101950501 Translate TFG Anaplastic large cell lymphoma
6 199890 5 4500000 23300000 Gain Anaplastic large cell lymphoma
7 264349 X 64804235 64878518 Translate MSN Anaplastic large cell lymphoma
8 300361 11 128069198 128187521 Translocation FLI1 Anaplastic large cell lymphoma
9 303153 2 29269143 29997936 Translocation ALK Anaplastic large cell lymphoma
10 303499 22 27994016 28026515 Translocation EWSR1 Anaplastic large cell lymphoma
11 304007 5 170747402 170770493 Translocation NPM1 Anaplastic large cell lymphoma

Expression for Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Anaplastic Large Cell Lymphoma.

Pathways for Anaplastic Large Cell Lymphoma

Pathways related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 CLU CSF1R IL9 JAK3 JUNB MCL1
2
Show member pathways
13.68 ALK CSF1R IL9 JAK3 JUNB MUC1
3
Show member pathways
13.18 ALK CSF1R IL9 JAK3 JUNB STAT3
4
Show member pathways
13.02 CSF1R IL9 JAK3 JUNB MCL1 MUC1
5 12.13 GZMB JAK3 JUNB PAX5 PTPRC STAT3
6
Show member pathways
12.03 IL9 JAK3 MCL1 STAT3
7
Show member pathways
11.73 GZMB JAK3 STAT3
8
Show member pathways
11.65 JUNB MCL1 STAT3
9 11.61 CSF1R JAK3 PTPRC STAT3
10 11.6 GZMB IL9 PTPRC
11 11.58 CSF1R PAX5 PPID
12
Show member pathways
11.3 IL9 JAK3 STAT3
13
Show member pathways
11.26 CSF1R JAK3 STAT3
14 11.19 JAK3 PTPRC STAT3
15 11.08 JAK3 JUNB MCL1 MUC1 STAT3
16 10.98 PAX5 PTPRC STAT3 TNFRSF8
17 10.91 GZMB MCL1

GO Terms for Anaplastic Large Cell Lymphoma

Biological processes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.72 CLU GZMB MCL1 PPID TNFSF8
2 inflammatory response GO:0006954 9.35 CSF1R IL9 JAK3 STAT3 TNFRSF8
3 response to cytokine GO:0034097 9.33 JUNB MCL1 STAT3
4 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.26 JAK3 STAT3
5 regulation of cell cycle GO:0051726 8.8 JUNB PTPRC STAT3

Molecular functions related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.13 JUNB PPID STAT3
2 protein phosphatase binding GO:0019903 8.8 CSF1R JAK3 STAT3

Sources for Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....